nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Diabetes insipidus—Riluzole—amyotrophic lateral sclerosis	0.0621	0.212	CcSEcCtD
Lithium—GRIA3—nerve—amyotrophic lateral sclerosis	0.0331	0.147	CbGeAlD
Lithium—GSK3B—nerve—amyotrophic lateral sclerosis	0.0286	0.128	CbGeAlD
Lithium—Salivary gland enlargement—Riluzole—amyotrophic lateral sclerosis	0.0211	0.072	CcSEcCtD
Lithium—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.0157	0.0537	CcSEcCtD
Lithium—GSK3B—embryo—amyotrophic lateral sclerosis	0.0134	0.0598	CbGeAlD
Lithium—GRIA3—medulla oblongata—amyotrophic lateral sclerosis	0.00989	0.0441	CbGeAlD
Lithium—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00932	0.0318	CcSEcCtD
Lithium—GRIA3—spinal cord—amyotrophic lateral sclerosis	0.00882	0.0393	CbGeAlD
Lithium—IMPA1—nervous system—amyotrophic lateral sclerosis	0.00874	0.039	CbGeAlD
Lithium—GSK3B—medulla oblongata—amyotrophic lateral sclerosis	0.00857	0.0382	CbGeAlD
Lithium—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00843	0.0288	CcSEcCtD
Lithium—IMPA1—central nervous system—amyotrophic lateral sclerosis	0.00842	0.0375	CbGeAlD
Lithium—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00785	0.0268	CcSEcCtD
Lithium—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00778	0.0265	CcSEcCtD
Lithium—GSK3B—spinal cord—amyotrophic lateral sclerosis	0.00764	0.034	CbGeAlD
Lithium—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00752	0.0257	CcSEcCtD
Lithium—GSK3A—medulla oblongata—amyotrophic lateral sclerosis	0.00745	0.0332	CbGeAlD
Lithium—GRIA3—nervous system—amyotrophic lateral sclerosis	0.00743	0.0331	CbGeAlD
Lithium—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00723	0.0247	CcSEcCtD
Lithium—GRIA3—central nervous system—amyotrophic lateral sclerosis	0.00716	0.0319	CbGeAlD
Lithium—GRIA3—cerebellum—amyotrophic lateral sclerosis	0.007	0.0312	CbGeAlD
Lithium—IMPA1—brain—amyotrophic lateral sclerosis	0.00668	0.0298	CbGeAlD
Lithium—GSK3A—spinal cord—amyotrophic lateral sclerosis	0.00664	0.0296	CbGeAlD
Lithium—GSK3B—nervous system—amyotrophic lateral sclerosis	0.00644	0.0287	CbGeAlD
Lithium—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00623	0.0213	CcSEcCtD
Lithium—GSK3B—central nervous system—amyotrophic lateral sclerosis	0.0062	0.0276	CbGeAlD
Lithium—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00619	0.0211	CcSEcCtD
Lithium—GSK3B—cerebellum—amyotrophic lateral sclerosis	0.00606	0.027	CbGeAlD
Lithium—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00596	0.0204	CcSEcCtD
Lithium—GRIA3—brain—amyotrophic lateral sclerosis	0.00568	0.0253	CbGeAlD
Lithium—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0193	CcSEcCtD
Lithium—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0193	CcSEcCtD
Lithium—GSK3A—nervous system—amyotrophic lateral sclerosis	0.0056	0.0249	CbGeAlD
Lithium—GSK3A—central nervous system—amyotrophic lateral sclerosis	0.00539	0.024	CbGeAlD
Lithium—Coma—Riluzole—amyotrophic lateral sclerosis	0.00535	0.0183	CcSEcCtD
Lithium—GSK3A—cerebellum—amyotrophic lateral sclerosis	0.00527	0.0235	CbGeAlD
Lithium—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00513	0.0175	CcSEcCtD
Lithium—IMPA2—brain—amyotrophic lateral sclerosis	0.00501	0.0224	CbGeAlD
Lithium—GSK3B—brain—amyotrophic lateral sclerosis	0.00492	0.0219	CbGeAlD
Lithium—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0152	CcSEcCtD
Lithium—GSK3A—brain—amyotrophic lateral sclerosis	0.00428	0.0191	CbGeAlD
Lithium—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.004	0.0136	CcSEcCtD
Lithium—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00395	0.0135	CcSEcCtD
Lithium—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00376	0.0128	CcSEcCtD
Lithium—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00375	0.0128	CcSEcCtD
Lithium—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00338	0.0116	CcSEcCtD
Lithium—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00334	0.0114	CcSEcCtD
Lithium—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00332	0.0113	CcSEcCtD
Lithium—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0102	CcSEcCtD
Lithium—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00999	CcSEcCtD
Lithium—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00897	CcSEcCtD
Lithium—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00887	CcSEcCtD
Lithium—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00861	CcSEcCtD
Lithium—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00856	CcSEcCtD
Lithium—Tremor—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00819	CcSEcCtD
Lithium—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00803	CcSEcCtD
Lithium—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00799	CcSEcCtD
Lithium—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00785	CcSEcCtD
Lithium—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00784	CcSEcCtD
Lithium—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00768	CcSEcCtD
Lithium—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00757	CcSEcCtD
Lithium—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00744	CcSEcCtD
Lithium—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00735	CcSEcCtD
Lithium—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00728	CcSEcCtD
Lithium—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00719	CcSEcCtD
Lithium—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00713	CcSEcCtD
Lithium—Shock—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00702	CcSEcCtD
Lithium—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0068	CcSEcCtD
Lithium—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00666	CcSEcCtD
Lithium—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0065	CcSEcCtD
Lithium—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00634	CcSEcCtD
Lithium—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00628	CcSEcCtD
Lithium—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0062	CcSEcCtD
Lithium—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00615	CcSEcCtD
Lithium—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00588	CcSEcCtD
Lithium—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00583	CcSEcCtD
Lithium—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00564	CcSEcCtD
Lithium—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00564	CcSEcCtD
Lithium—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00512	CcSEcCtD
Lithium—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00488	CcSEcCtD
Lithium—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00472	CcSEcCtD
Lithium—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00453	CcSEcCtD
Lithium—Rash—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0045	CcSEcCtD
Lithium—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00449	CcSEcCtD
Lithium—Headache—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00447	CcSEcCtD
Lithium—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00424	CcSEcCtD
Lithium—IMPA2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000935	0.00194	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000925	0.00192	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—CASP9—amyotrophic lateral sclerosis	0.0009	0.00186	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000899	0.00186	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—CASP9—amyotrophic lateral sclerosis	0.000895	0.00185	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—CASP9—amyotrophic lateral sclerosis	0.000891	0.00185	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—GSR—amyotrophic lateral sclerosis	0.000888	0.00184	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—CASP9—amyotrophic lateral sclerosis	0.000886	0.00184	CbGpPWpGaD
Lithium—GSK3B—Cardiac Progenitor Differentiation—IGF1—amyotrophic lateral sclerosis	0.000885	0.00183	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—CASP9—amyotrophic lateral sclerosis	0.000874	0.00181	CbGpPWpGaD
Lithium—IMPA2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000863	0.00179	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—IGF1—amyotrophic lateral sclerosis	0.000859	0.00178	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VCP—amyotrophic lateral sclerosis	0.000858	0.00178	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.000856	0.00177	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RTN4—amyotrophic lateral sclerosis	0.000849	0.00176	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—ERBB4—amyotrophic lateral sclerosis	0.000846	0.00175	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000842	0.00174	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—CASP9—amyotrophic lateral sclerosis	0.000834	0.00173	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—CASP9—amyotrophic lateral sclerosis	0.000834	0.00173	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—CASP9—amyotrophic lateral sclerosis	0.000834	0.00173	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000833	0.00173	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000827	0.00171	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—ERBB4—amyotrophic lateral sclerosis	0.000826	0.00171	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.00082	0.0017	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—ERBB4—amyotrophic lateral sclerosis	0.00082	0.0017	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.000819	0.0017	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.000819	0.0017	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.000816	0.00169	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000814	0.00169	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.000806	0.00167	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB4—amyotrophic lateral sclerosis	0.000801	0.00166	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000785	0.00163	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—APOE—amyotrophic lateral sclerosis	0.000778	0.00161	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000776	0.00161	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—MMP9—amyotrophic lateral sclerosis	0.000775	0.00161	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—CASP9—amyotrophic lateral sclerosis	0.000772	0.0016	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.00077	0.0016	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000769	0.00159	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000766	0.00159	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000766	0.00159	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000762	0.00158	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000759	0.00157	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—amyotrophic lateral sclerosis	0.000748	0.00155	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—CASP9—amyotrophic lateral sclerosis	0.000739	0.00153	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000739	0.00153	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—PFN1—amyotrophic lateral sclerosis	0.000718	0.00149	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000714	0.00148	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000714	0.00148	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000714	0.00148	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000709	0.00147	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.000707	0.00147	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—CASP9—amyotrophic lateral sclerosis	0.000707	0.00147	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000705	0.00146	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000701	0.00145	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000698	0.00145	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—CASP9—amyotrophic lateral sclerosis	0.000696	0.00144	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000693	0.00144	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—CASP3—amyotrophic lateral sclerosis	0.000691	0.00143	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000684	0.00142	CbGpPWpGaD
Lithium—GSK3A—Disease—TPK1—amyotrophic lateral sclerosis	0.000684	0.00142	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000679	0.00141	CbGpPWpGaD
Lithium—GSK3B—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000671	0.00139	CbGpPWpGaD
Lithium—GSK3B—Aurora A signaling—TP53—amyotrophic lateral sclerosis	0.000671	0.00139	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—CASP9—amyotrophic lateral sclerosis	0.000665	0.00138	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—CASP9—amyotrophic lateral sclerosis	0.000662	0.00137	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000661	0.00137	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—ERBB4—amyotrophic lateral sclerosis	0.000661	0.00137	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—CASP9—amyotrophic lateral sclerosis	0.000658	0.00136	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—CASP9—amyotrophic lateral sclerosis	0.000655	0.00136	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—CASP9—amyotrophic lateral sclerosis	0.000646	0.00134	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000636	0.00132	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.000633	0.00131	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000632	0.00131	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000632	0.00131	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000632	0.00131	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—CASP9—amyotrophic lateral sclerosis	0.000616	0.00128	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—CASP9—amyotrophic lateral sclerosis	0.000616	0.00128	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—CASP9—amyotrophic lateral sclerosis	0.000616	0.00128	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.000613	0.00127	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000612	0.00127	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000611	0.00127	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.000605	0.00125	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.000605	0.00125	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.000603	0.00125	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000597	0.00124	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.000596	0.00123	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—CASP3—amyotrophic lateral sclerosis	0.000586	0.00121	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000584	0.00121	CbGpPWpGaD
Lithium—GRIA3—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000578	0.0012	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000573	0.00119	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—CASP9—amyotrophic lateral sclerosis	0.00057	0.00118	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.000569	0.00118	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000568	0.00118	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000566	0.00117	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000563	0.00117	CbGpPWpGaD
Lithium—GSK3A—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000561	0.00116	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000561	0.00116	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—MMP9—amyotrophic lateral sclerosis	0.000553	0.00115	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—amyotrophic lateral sclerosis	0.000553	0.00114	CbGpPWpGaD
Lithium—GSK3A—Disease—VTA1—amyotrophic lateral sclerosis	0.000547	0.00113	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000546	0.00113	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000545	0.00113	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000527	0.00109	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000527	0.00109	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000527	0.00109	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.000523	0.00108	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000518	0.00107	CbGpPWpGaD
Lithium—GSK3B—LKB1 signaling events—TP53—amyotrophic lateral sclerosis	0.000516	0.00107	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000516	0.00107	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IGF1—amyotrophic lateral sclerosis	0.000512	0.00106	CbGpPWpGaD
Lithium—GSK3B—Disease—TPK1—amyotrophic lateral sclerosis	0.000505	0.00105	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000503	0.00104	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000496	0.00103	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—CASP3—amyotrophic lateral sclerosis	0.000495	0.00103	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—ERBB4—amyotrophic lateral sclerosis	0.000488	0.00101	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000486	0.00101	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.00047	0.000974	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000467	0.000968	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—TP53—amyotrophic lateral sclerosis	0.000443	0.000919	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000441	0.000913	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—CASP3—amyotrophic lateral sclerosis	0.000438	0.000908	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.00043	0.000891	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000429	0.00089	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.00042	0.00087	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000415	0.000859	CbGpPWpGaD
Lithium—GSK3A—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000414	0.000858	CbGpPWpGaD
Lithium—GSK3B—Disease—VTA1—amyotrophic lateral sclerosis	0.000404	0.000837	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000403	0.000835	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000402	0.000832	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—amyotrophic lateral sclerosis	0.000401	0.00083	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000399	0.000826	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000398	0.000825	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000392	0.000812	CbGpPWpGaD
Lithium—IMPA2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000381	0.000789	CbGpPWpGaD
Lithium—GSK3A—Disease—PLB1—amyotrophic lateral sclerosis	0.000375	0.000776	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000367	0.000759	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000359	0.000744	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000356	0.000738	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00035	0.000725	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.00034	0.000705	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000339	0.000703	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000338	0.000701	CbGpPWpGaD
Lithium—GSK3A—Disease—VCP—amyotrophic lateral sclerosis	0.000334	0.000692	CbGpPWpGaD
Lithium—GSK3A—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000331	0.000685	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.00033	0.000685	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000324	0.000671	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	0.000319	0.00066	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—amyotrophic lateral sclerosis	0.000317	0.000657	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000312	0.000646	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000311	0.000645	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	0.000308	0.000638	CbGpPWpGaD
Lithium—GSK3B—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000306	0.000634	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000306	0.000634	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000294	0.00061	CbGpPWpGaD
Lithium—IMPA2—Metabolism—APOE—amyotrophic lateral sclerosis	0.000288	0.000597	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.00028	0.000581	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000277	0.000575	CbGpPWpGaD
Lithium—GSK3B—Disease—PLB1—amyotrophic lateral sclerosis	0.000277	0.000574	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000266	0.000552	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000262	0.000544	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—amyotrophic lateral sclerosis	0.000259	0.000536	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—amyotrophic lateral sclerosis	0.000259	0.000536	CbGpPWpGaD
Lithium—IMPA1—Metabolism—APOE—amyotrophic lateral sclerosis	0.000257	0.000532	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000256	0.00053	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000253	0.000524	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000251	0.000521	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.00025	0.000519	CbGpPWpGaD
Lithium—GSK3B—Disease—VCP—amyotrophic lateral sclerosis	0.000247	0.000511	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000247	0.000511	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—amyotrophic lateral sclerosis	0.000245	0.000508	CbGpPWpGaD
Lithium—GSK3B—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000244	0.000506	CbGpPWpGaD
Lithium—GSK3A—Disease—CST3—amyotrophic lateral sclerosis	0.00024	0.000497	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000239	0.000496	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000239	0.000496	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000234	0.000484	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—C3—amyotrophic lateral sclerosis	0.00023	0.000477	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.00023	0.000476	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000226	0.000469	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000221	0.000459	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000212	0.000439	CbGpPWpGaD
Lithium—GSK3A—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000211	0.000438	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	0.000208	0.000431	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000205	0.000425	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000201	0.000417	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000199	0.000412	CbGpPWpGaD
Lithium—GSK3A—Immune System—ATF1—amyotrophic lateral sclerosis	0.000198	0.000411	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000197	0.000409	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000197	0.000408	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000194	0.000402	CbGpPWpGaD
Lithium—GSK3A—Immune System—CASP9—amyotrophic lateral sclerosis	0.000189	0.000391	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000185	0.000383	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000182	0.000378	CbGpPWpGaD
Lithium—GSK3B—Disease—CST3—amyotrophic lateral sclerosis	0.000177	0.000367	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000177	0.000366	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000176	0.000364	CbGpPWpGaD
Lithium—GSK3A—Disease—CASP9—amyotrophic lateral sclerosis	0.000174	0.000361	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000173	0.000358	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—C3—amyotrophic lateral sclerosis	0.00017	0.000353	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000167	0.000347	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000164	0.000339	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000162	0.000335	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	0.00016	0.000331	CbGpPWpGaD
Lithium—GSK3B—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000156	0.000323	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000155	0.000321	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000152	0.000315	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000151	0.000313	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.00015	0.000311	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB4—amyotrophic lateral sclerosis	0.000149	0.000309	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000149	0.000308	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000147	0.000304	CbGpPWpGaD
Lithium—GSK3B—Immune System—ATF1—amyotrophic lateral sclerosis	0.000146	0.000303	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP9—amyotrophic lateral sclerosis	0.000139	0.000289	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000137	0.000283	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000136	0.000281	CbGpPWpGaD
Lithium—GSK3A—Immune System—C3—amyotrophic lateral sclerosis	0.000134	0.000278	CbGpPWpGaD
Lithium—GSK3B—Disease—CASP9—amyotrophic lateral sclerosis	0.000129	0.000267	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000128	0.000265	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000122	0.000253	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	0.000121	0.00025	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000119	0.000247	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—amyotrophic lateral sclerosis	0.000115	0.000239	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000112	0.000233	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB4—amyotrophic lateral sclerosis	0.00011	0.000228	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000108	0.000224	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000104	0.000216	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000101	0.000209	CbGpPWpGaD
Lithium—GSK3B—Immune System—C3—amyotrophic lateral sclerosis	9.92e-05	0.000206	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.82e-05	0.000203	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	9.69e-05	0.000201	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.47e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.02e-05	0.000187	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.68e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—amyotrophic lateral sclerosis	8.53e-05	0.000177	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.08e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—amyotrophic lateral sclerosis	7.91e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.72e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.26e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.68e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.41e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.97e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—amyotrophic lateral sclerosis	5.84e-05	0.000121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.14e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.93e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.86e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.36e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.8e-05	7.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.59e-05	7.43e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.29e-05	6.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.22e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.43e-05	5.04e-05	CbGpPWpGaD
